Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.50 |
| ▸ | MMP1 | P03956 | 2/20 | 0.47 |
| ▸ | MMP9 | P14780 | 2/20 | 0.47 |
| ▸ | MMP14 | P50281 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 7/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31311637 | 1.00 | AAK1 (0.50) | AAK1MMP1MMP9MMP14HDAC4 | |
| SCHEMBL3039988 | 1.00 | AAK1 (0.50) | AAK1MMP1MMP9MMP14HDAC4 | |
| SCHEMBL25069123 | 0.92 | AAK1 (0.52) | AAK1MMP1MMP9MMP14HDAC4 | |
| SCHEMBL19125612 | 0.90 | MMP1 (0.48) | AAK1MMP1MMP9MMP14HDAC4 | |
| SCHEMBL3039102 | 0.89 | AAK1 (0.45) | AAK1MMP1MMP9MMP14HDAC4 | |
| SCHEMBL3037261 | 0.89 | AAK1 (0.45) | AAK1MMP1MMP9MMP14HDAC4 | |
| SCHEMBL2098571 | 0.89 | AAK1 (0.45) | AAK1MMP1MMP9MMP14HDAC4 | |
| SCHEMBL22679471 | 0.87 | HDAC4 (0.57) | AAK1HDAC4HDAC1HDAC6CTSS | |
| SCHEMBL16317185 | 0.84 | GAA (0.47) | AAK1HDAC4HDAC1HDAC6CTSS | |
| SCHEMBL22125910 | 0.84 | CTSS (0.47) | AAK1MMP1HDAC4HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200181095-A1 | SELECTIVE MATRIX METALLOPROTEINASE-13 INHIBITORS | FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES (US) | 2020-06-11 | — | — | US | disclosed |
| US-20100166706-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-07-01 | — | — | US | disclosed |
| EP-1713822-B1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-03-17 | — | — | EP | disclosed |
| US-7671032-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2010-03-02 | — | — | US | disclosed |
| US-20100003216-A1 | HCV NS-3 Serine Protease Inhibitors | MEDIVIR AB (SE) | 2010-01-07 | — | — | US | disclosed |
| EP-1713823-B1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2009-11-11 | — | — | EP | disclosed |
| US-7608590-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2009-10-27 | — | — | US | disclosed |
| EP-1881002-A1 | HCV NS-3 serine protease inhibitors | Tibotec Pharmaceuticals Ltd. (IE) | 2008-01-23 | — | — | EP | disclosed |
| EP-1881001-A1 | HCV NS-3 serine protease inhibitors | Tibotec Pharmaceuticals Ltd. (IE) | 2008-01-23 | — | — | EP | disclosed |
| US-20070203072-A1 | Hcv Ns-3 Serine Protease Inhibitors | MEDIVIR AB (SE) | 2007-08-30 | — | — | US | disclosed |
| US-20070161574-A1 | Hcv ns-3 serine protease inhibitors | MEDIVIR AB (SE) | 2007-07-12 | — | — | US | disclosed |
| EP-1713823-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005073195-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003216-A1 | HCV NS-3 Serine Protease Inhibitors | SPINT2, SF3A3, GTF3C3 | AAK1 2671/4885MMP1 2768/4885MMP9 3735/4885 |
| US-20100166706-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | HPN, CPN1, PRSS1 | AAK1 2325/4885MMP1 1775/4885MMP9 2502/4885 |
| US-20070161574-A1 | Hcv ns-3 serine protease inhibitors | PRSS1, HPN, SPINT2 | AAK1 2132/4885MMP1 2329/4885MMP9 2878/4885 |
| US-20070203072-A1 | Hcv Ns-3 Serine Protease Inhibitors | HPN, CPN1, PRSS1 | AAK1 2213/4885MMP1 1837/4885MMP9 2597/4885 |
| US-20200181095-A1 | SELECTIVE MATRIX METALLOPROTEINASE-13 INHIBITORS | MMP13, MMP17, MMP16 | AAK1 4744/4885MMP1 17/4885MMP9 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.